|
KR101483215B1
(ko)
*
|
2010-01-29 |
2015-01-16 |
한미약품 주식회사 |
단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
|
|
CN110003219A
(zh)
*
|
2010-07-13 |
2019-07-12 |
弗·哈夫曼-拉罗切有限公司 |
作为irak4调节剂的吡唑并[1,5a]嘧啶和噻吩并[3,2b]嘧啶衍生物
|
|
WO2012097013A1
(en)
*
|
2011-01-10 |
2012-07-19 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
US9169260B2
(en)
|
2011-03-22 |
2015-10-27 |
Merck Sharp & Dohme Corp. |
Amidopyrazole inhibitors of interleukin receptor-associated kinases
|
|
US9309250B2
(en)
|
2011-06-22 |
2016-04-12 |
Vertex Pharmaceuticals Incorporated |
Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
|
|
BR112014015720B1
(pt)
*
|
2011-12-30 |
2020-03-17 |
Hanmi Pharm. Co., Ltd. |
Derivados de tieno[3,2-d]pirimidina, composição farmacêutica e uso dos mesmos para a prevenção ou tratamento de uma doença causada por ativação anormal de uma proteína quinase
|
|
EP2802590B1
(en)
|
2012-01-10 |
2017-03-01 |
F. Hoffmann-La Roche AG |
Thienopyrimidine compounds
|
|
JP6126131B2
(ja)
*
|
2012-01-10 |
2017-05-10 |
ニンバス アイリス， インコーポレイテッド |
Ｉｒａｋ阻害剤およびその使用
|
|
WO2014003483A1
(en)
*
|
2012-06-29 |
2014-01-03 |
Hanmi Pharm. Co., Ltd. |
Fused pyrimidine derivatives having inhibitory activity on fms kinases
|
|
JP6189434B2
(ja)
*
|
2012-07-10 |
2017-08-30 |
アレス トレーディング ソシエテ アノニム |
ピリミジンピラゾリル誘導体
|
|
WO2014011902A1
(en)
*
|
2012-07-11 |
2014-01-16 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
WO2014011906A2
(en)
*
|
2012-07-11 |
2014-01-16 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
WO2014011911A2
(en)
*
|
2012-07-11 |
2014-01-16 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
SI2941432T1
(en)
|
2012-12-07 |
2018-07-31 |
Vertex Pharmaceuticals Incorporated |
2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR
|
|
CA2890911A1
(en)
|
2013-01-10 |
2014-07-17 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
ES2649156T3
(es)
|
2013-01-14 |
2018-01-10 |
Incyte Holdings Corporation |
Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
|
|
PE20191245A1
(es)
|
2013-01-15 |
2019-09-18 |
Incyte Holdings Corp |
Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
|
|
US8778365B1
(en)
|
2013-01-31 |
2014-07-15 |
Merz Pharmaceuticals, Llc |
Topical compositions and methods for making and using same
|
|
EP2970288A1
(en)
*
|
2013-03-15 |
2016-01-20 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
US8957078B2
(en)
|
2013-03-15 |
2015-02-17 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
WO2014143240A1
(en)
|
2013-03-15 |
2014-09-18 |
Vertex Pharmaceuticals Incorporated |
Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
WO2015006181A1
(en)
|
2013-07-11 |
2015-01-15 |
Merck Sharp & Dohme Corp. |
Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4)
|
|
EA201690458A1
(ru)
|
2013-08-23 |
2016-07-29 |
Инсайт Корпорейшн |
Фуро- и тиенопиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы
|
|
CN106232122A
(zh)
|
2013-09-27 |
2016-12-14 |
林伯士艾瑞斯公司 |
Irak抑制剂和其用途
|
|
PT3077397T
(pt)
|
2013-12-06 |
2020-01-22 |
Vertex Pharma |
Composto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inibidor da atr quinase, a sua preparação, diferentes formas sólidas e derivados radiomarcados do mesmo
|
|
CA2932353A1
(en)
|
2013-12-13 |
2015-06-18 |
Steven P. Treon |
Methods to treat lymphoplasmacytic lymphoma
|
|
EP3079683A4
(en)
|
2013-12-13 |
2017-12-20 |
Dana-Farber Cancer Institute, Inc. |
Methods to treat lymphoplasmacytic lymphoma
|
|
TWI667233B
(zh)
|
2013-12-19 |
2019-08-01 |
德商拜耳製藥公司 |
新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
|
|
EP3092226B1
(en)
*
|
2014-01-10 |
2019-03-13 |
Aurigene Discovery Technologies Limited |
Indazole compounds as irak4 inhibitors
|
|
LT3466955T
(lt)
|
2014-01-13 |
2021-02-25 |
Aurigene Discovery Technologies Limited |
Oksazol[4,5-b]piridino ir tiazol[4,5-b]piridino darinių, kaip irak4 inhibitorių, skirtų vėžio gydymui, gamybos būdas
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
JP2017516850A
(ja)
|
2014-05-23 |
2017-06-22 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｊａｋ阻害剤である５−クロロ−２−ジフルオロメトキシフェニルピラゾロピリミジン化合物
|
|
MX373102B
(es)
|
2014-06-05 |
2020-04-17 |
Vertex Pharma |
Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útil como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparación de tal compuesto y diferentes formas sólidas del mismo.
|
|
SG11201610500WA
(en)
|
2014-06-17 |
2017-01-27 |
Vertex Pharma |
Method for treating cancer using a combination of chk1 and atr inhibitors
|
|
US9822124B2
(en)
|
2014-07-14 |
2017-11-21 |
Incyte Corporation |
Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
|
|
US9580418B2
(en)
|
2014-07-14 |
2017-02-28 |
Incyte Corporation |
Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
|
|
EP3715346B1
(en)
|
2014-10-22 |
2024-01-03 |
Dana-Farber Cancer Institute, Inc. |
Thiazolyl-containing compounds for treating proliferative diseases
|
|
US20170333435A1
(en)
|
2014-11-06 |
2017-11-23 |
Lysosomal Therapeutics Inc. |
Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
|
|
US20180185368A1
(en)
|
2014-11-06 |
2018-07-05 |
Lysosomal Therapeutics Inc. |
Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
|
|
EP4406616A3
(en)
|
2014-11-06 |
2024-11-06 |
Bial-R&D Investments, S.A. |
Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
|
|
JP6787892B2
(ja)
*
|
2014-11-20 |
2020-11-18 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ |
Ｉｒａｋインヒビターとしてのヘテロアリール化合物及びその使用
|
|
WO2016144847A1
(en)
*
|
2015-03-12 |
2016-09-15 |
Merck Sharp & Dohme Corp. |
Pyrrolopyridazine inhibitors of irak4 activity
|
|
US10155765B2
(en)
|
2015-03-12 |
2018-12-18 |
Merck Sharp & Dohme Corp. |
Carboxamide inhibitors of IRAK4 activity
|
|
WO2016144848A1
(en)
*
|
2015-03-12 |
2016-09-15 |
Merck Sharp & Dohme Corp. |
Pyrrolotriazine inhibitors of irak4 activity
|
|
WO2016144849A1
(en)
*
|
2015-03-12 |
2016-09-15 |
Merck Sharp & Dohme Corp. |
Thienopyrazine inhibitors of irak4 activity
|
|
US10329294B2
(en)
|
2015-03-12 |
2019-06-25 |
Merck Sharp & Dohme Corp. |
Pyrazolopyrimidine inhibitors of IRAK4 activity
|
|
WO2016196244A1
(en)
|
2015-05-29 |
2016-12-08 |
Incyte Corporation |
Pyridineamine compounds useful as pim kinase inhibitors
|
|
WO2017004134A1
(en)
*
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
|
JP2018524372A
(ja)
*
|
2015-07-15 |
2018-08-30 |
アウリジーン ディスカバリー テクノロジーズ リミテッド |
Ｉｒａｋ−４阻害剤としてのインダゾール及びアザインダゾール化合物
|
|
TWI734699B
(zh)
|
2015-09-09 |
2021-08-01 |
美商英塞特公司 |
Ｐｉｍ激酶抑制劑之鹽
|
|
CN108348512B
(zh)
*
|
2015-09-17 |
2021-09-03 |
希望之城 |
Pcna抑制剂
|
|
AU2016331955B2
(en)
|
2015-09-30 |
2022-07-21 |
Vertex Pharmaceuticals Incorporated |
Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
|
|
CN105237414B
(zh)
*
|
2015-09-30 |
2017-03-22 |
浙江永宁药业股份有限公司 |
ivacaftor中间体及其制备方法和用途
|
|
US9920032B2
(en)
|
2015-10-02 |
2018-03-20 |
Incyte Corporation |
Heterocyclic compounds useful as pim kinase inhibitors
|
|
CN108473498B
(zh)
*
|
2015-12-22 |
2021-11-02 |
豪夫迈·罗氏有限公司 |
作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物
|
|
EP3440081A4
(en)
|
2016-04-06 |
2019-09-18 |
Lysosomal Therapeutics Inc. |
PYRROLO [1,2-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER
|
|
CA3020305A1
(en)
|
2016-04-06 |
2017-10-12 |
Lysosomal Therapeutics Inc. |
Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
|
|
AU2017246455B2
(en)
|
2016-04-06 |
2021-09-30 |
Bial - R&D Investments, S.A. |
Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
|
|
EP3452045A1
(en)
*
|
2016-05-04 |
2019-03-13 |
Lysosomal Therapeutics Inc. |
Methods of treatment and combination therapies using gcase activator heterobicyclic and related compounds
|
|
KR102530515B1
(ko)
|
2016-05-05 |
2023-05-09 |
비알 - 알&디 인베스트먼츠, 에스.에이. |
치환된 이미다조[1,2-b]피리다진, 치환된 이미다조[1,5-b]피리다진, 관련 화합물, 및 의학적 장애의 치료에서의 그의 용도
|
|
WO2017192931A1
(en)
|
2016-05-05 |
2017-11-09 |
Lysosomal Therapeutics Inc. |
SUBSTITUTED IMDAZO[1,2-α]PYRIDINES, SUBSTITUTED IMIDAZO[1,2-α]PYRAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
|
|
CN106222183B
(zh)
*
|
2016-07-25 |
2019-11-08 |
南通大学 |
靶向人irak1基因的小干扰rna及其应用
|
|
CN109890829B
(zh)
*
|
2016-11-02 |
2022-07-15 |
豪夫迈·罗氏有限公司 |
作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物
|
|
MX394556B
(es)
*
|
2017-02-01 |
2025-03-24 |
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd |
Derivados de n1-(4-(5-(ciclopropilmetil)-1-metil-1h-pirazol-4-il) piridin-2-il) ciclohexano-1,4-diamina y compuestos relacionados como inhibidores de ck1 y/o irak1 para tratar cáncer.
|
|
TW202340194A
(zh)
|
2017-02-16 |
2023-10-16 |
美商基利科學股份有限公司 |
吡咯并[1,2-b]嗒𠯤衍生物
|
|
EP3600270B1
(en)
|
2017-03-31 |
2023-06-14 |
Aurigene Oncology Limited |
Compounds and compositions for treating hematological disorders
|
|
CN106946890A
(zh)
*
|
2017-04-26 |
2017-07-14 |
中国药科大学 |
吡啶类irak4抑制剂、其制备方法及应用
|
|
MX387969B
(es)
|
2017-05-22 |
2025-03-19 |
Hoffmann La Roche |
Composiciones y compuestos terapéuticos, y métodos para su uso.
|
|
WO2018234345A1
(en)
*
|
2017-06-21 |
2018-12-27 |
F. Hoffmann-La Roche Ag |
PYRAZOLO [1,5A] PYRIMIDINE DERIVATIVES AS MODULATORS OF IRAK4
|
|
EP3642201A1
(en)
*
|
2017-06-21 |
2020-04-29 |
H. Hoffnabb-La Roche Ag |
Isoindolinone derivatives as irak4 modulators
|
|
JP2020524692A
(ja)
*
|
2017-06-21 |
2020-08-20 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｉｒａｋ４調節因子としてのベンゾフラン
|
|
WO2019001460A1
(zh)
*
|
2017-06-27 |
2019-01-03 |
南京明德新药研发股份有限公司 |
作为 irak4 抑制剂的稠环化合物
|
|
JP7114394B2
(ja)
*
|
2017-08-18 |
2022-08-08 |
住友化学株式会社 |
化合物、レジスト組成物及びレジストパターンの製造方法
|
|
WO2019060742A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc |
AGENTS FOR DEGRADING PROTEINS AND USES THEREOF
|
|
US11358948B2
(en)
|
2017-09-22 |
2022-06-14 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
|
HUE067356T2
(hu)
|
2017-10-31 |
2024-10-28 |
Curis Inc |
IRAK4 inhibitor és BCL-2 inhibitor kombinációban, rák kezelésére való felhasználásra
|
|
EP3710443A1
(en)
|
2017-11-17 |
2020-09-23 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
|
|
MX2020005563A
(es)
*
|
2017-11-30 |
2020-10-28 |
Hanmi Pharm Ind Co Ltd |
Compuesto de tieno[3,2-d]pirimidina que tiene actividad inhibidora para proteina cinasa.
|
|
WO2019111218A1
(en)
|
2017-12-08 |
2019-06-13 |
Cadila Healthcare Limited |
Novel heterocyclic compounds as irak4 inhibitors
|
|
WO2019113487A1
(en)
|
2017-12-08 |
2019-06-13 |
Incyte Corporation |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
WO2019140387A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
WO2019140380A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
IL277408B2
(en)
|
2018-04-05 |
2024-08-01 |
Merck Patent Gmbh |
Heteroaryl compounds as IRAK type II inhibitors and their use
|
|
WO2020010227A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
WO2020010177A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Tricyclic crbn ligands and uses thereof
|
|
TWI842978B
(zh)
|
2018-07-13 |
2024-05-21 |
美商基利科學股份有限公司 |
衍生物
|
|
CN110862375B
(zh)
|
2018-08-27 |
2022-10-25 |
深圳铂立健医药有限公司 |
吡唑化合物及其药物组合物和应用
|
|
US11155560B2
(en)
|
2018-10-30 |
2021-10-26 |
Kronos Bio, Inc. |
Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity
|
|
CA3119773A1
(en)
|
2018-11-30 |
2020-06-04 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
JP7576581B2
(ja)
*
|
2019-06-27 |
2024-10-31 |
バイオジェン・エムエイ・インコーポレイテッド |
イミダゾ［１，２－ａ］ピリジニル誘導体及び疾患の処置におけるそれらの使用
|
|
PH12022500002A1
(en)
|
2019-06-28 |
2023-04-03 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
WO2021011868A1
(en)
|
2019-07-17 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
WO2021066559A1
(en)
|
2019-10-02 |
2021-04-08 |
Kainos Medicine, Inc. |
N-(1h-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient
|
|
WO2021119159A1
(en)
|
2019-12-10 |
2021-06-17 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
|
EP4076524A4
(en)
|
2019-12-17 |
2023-11-29 |
Kymera Therapeutics, Inc. |
IRAQ DEGRADERS AND USES THEREOF
|
|
KR20220145325A
(ko)
|
2019-12-17 |
2022-10-28 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Irak 분해제 및 이의 용도
|
|
IL297050A
(en)
|
2020-04-04 |
2022-12-01 |
Pfizer |
Methods of treating the 2019 corona virus disease
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
MX2023003698A
(es)
|
2020-09-30 |
2023-06-15 |
Asahi Kasei Pharma Corp |
Compuesto biciclico que contiene nitrogeno y pirimidina.
|
|
US11866405B2
(en)
|
2020-12-10 |
2024-01-09 |
Astrazeneca Ab |
Substituted indazoles as IRAK4 inhibitors
|
|
CN116867758A
(zh)
|
2020-12-30 |
2023-10-10 |
凯麦拉医疗公司 |
Irak降解剂和其用途
|
|
US12171768B2
(en)
|
2021-02-15 |
2024-12-24 |
Kymera Therapeutics, Inc. |
IRAK4 degraders and uses thereof
|
|
CN116867494A
(zh)
|
2021-02-15 |
2023-10-10 |
凯麦拉医疗公司 |
Irak4降解剂和其用途
|
|
EP4319750A4
(en)
|
2021-04-08 |
2025-02-26 |
Curis, Inc. |
COMBINATION THERAPIES FOR THE TREATMENT OF CANCER
|
|
KR20240020735A
(ko)
|
2021-05-07 |
2024-02-15 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Cdk2 분해제 및 그 용도
|
|
KR102869914B1
(ko)
*
|
2021-10-28 |
2025-10-13 |
재단법인 대구경북첨단의료산업진흥재단 |
신규한 티에노[2,3-d]피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 또는 자가면역질환의 예방 또는 치료용 약학적 조성물
|
|
CA3236265A1
(en)
|
2021-10-29 |
2023-05-04 |
William Leong |
Irak4 degraders and synthesis thereof
|
|
CA3243560A1
(en)
|
2022-01-31 |
2023-08-03 |
Kymera Therapeutics, Inc. |
Iraqi Degradation Agents and Their Uses
|